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Background: Resistance to apoptosis induced by anti-cancer drugs is a major obstacle for the treatment of aggressive
forms of breast cancer. Galectin-7 (gal-7) was recently shown to be specifically expressed in basal-like but not in luminal
subtypes of human breast cancer.
Methods: We generated a mutant form of gal-7 (R74S). Arginine 74 is the structural equivalent of arginine 186 found
in human galectin-3. Mutation R186S was previously shown to abolish the biological function of galectin-3.
Results: Mutation of arginine 74 induced only limited and local changes to the gal-7 fold. Recombinant forms of R74S
and wtgal-7 were also equally effective at forming dimers in solution. Analysis of the thermodynamic parameters by
isothermal titration calorimetry (ITC) indicated, however, that binding of lactose to gal-7 was inhibited by the R74S
mutation. Using confocal microscopy and electron microscopy, we confirmed the expression of gal-7 in the
cytosolic and nuclear compartments of breast cancer cells and the ability of gal-7 to translocate to mitochondria.
The mutation at position 74, however, greatly reduced the expression of gal-7 in the nuclear and mitochondrial
compartments. Interestingly, cells expressing mutated gal-7 were equally if not even more resistant to drug-induced
apoptosis when compared to cells expressing wtgal-7. We also found that both wtgal-7 and R74S inhibited dox-induced
PARP-1 cleavage and p53 protein expression. The inhibition of p53 correlated with a decrease in p21 protein expression
and CDKN1A mRNA. Furthermore, analysis of nuclear and cytoplasmic fractions showed that both wild type and R74S
mutant gal-7 inhibited p53 nuclear translocation, possibly by increasing degradation of cytosolic p53.
Conclusions: These findings pose a challenge to the paradigm that has guided the design of galectin-specific inhibitors
for the treatment of cancer. This study suggests that targeting CRD-independent cytosolic gal-7 in breast cancer cells
may be a valuable strategy for the treatment of this disease. Our study will thus complement efforts towards improving
selectivity of targeted anticancer agents.
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Members of the galectin family are characterized by
their ability to bind β-galactosides via a highly con-
served carbohydrate recognition domain (CRD). They
play an important role in several physiological pro-
cesses, including embryonic development, intercellular
adhesion, host-pathogen interactions, cell migration, and
immune response [1]. They are normally classified accord-
ing to their structural organization. Galectins containing* Correspondence: yves.st-pierre@iaf.inrs.ca
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CRDs in tandem connected by a linker region (tandem-
repeat type) are galectins 4, 6, 8, 9 and 12. Galectin-3
is the only member of the third group and is a chimera-
type protein with one CRD connected to an unusual non-
lectin domain rich in proline and glycine.
Historically, galectins have been known as small extra-
cellular soluble that bind cell surface glycans, helping
organizing membrane domains and regulating the sig-
naling threshold and the receptor residency time [2].
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extracellular compartments. Intracellularly, they have
been reported to be exclusively/predominantly cyto-
solic, nuclear, mitochondrial, or distributed between
the distinct subcellular compartments. Finally, even
within a specific organelle, they appear to be distrib-
uted diffusely or to form aggregates or punctate struc-
tures. Such wide subcellular distribution significantly
complicate galectin-targeted anticancer therapy since
the pro- and the anti-tumoral functions of galectins
differ according their subcellular localization [3].
Galectin-7 (gal-7) is a prototype galectin that forms
homodimers [4]. Gal-7 is preferentially expressed in
stratified epithelia, including epidermis, cornea, oral
cavity, esophagus and rectal epithelium [5]. It is also
expressed in mammary myoepithelial cells in tissues of
normal individuals [6]. Its level of expression, however,
is significantly altered in various types of cancer [7].
For example, gal-7 is expressed at higher levels in aggres-
sive molecular subtypes of breast carcinoma, most notably
in basal-like breast cancer with an ER/PR/HER-2 negative
status [6]. Exogenous expression of gal-7 in breast cancer
cell lines that express low or undetectable levels of gal-7
resulted in an increased metastatic behavior to the lung
and bone and larger osteolytic lesions. Such pro-tumoral
function of gal-7 has been largely attributed to its abil-
ity to protect cancer cells from pro-apoptotic signals
[6,8]. Like other galectins, however, gal-7 is preferentially
expressed intracellularly, most notably in cytosolic, nu-
clear and mitochondrial compartments [9-12]. Whether
the resistance of breast cancer cells to apoptosis is
dependent on the intracellular localization of gal-7 re-
mains unknown. In the present work, we have addressed
this question by generating a mutant form of gal-7 (R74S)
with altered subcellular localization and tested its ability
to mediate resistance of breast cancer cells to drug-
induced cell death.
Methods
Tissue microarrays and immunohistochemistry
Representative specimens from our previous TMA ana-
lysis were immunostained for gal-7 using the Discovery
XT automated immunostainer (Ventana Medical Systems,
Tucson, AZ) [6]. Deparaffinized sections were incubated
in Cell Conditioning 1 (pH 8.0) for antigen retrieval and
then stained for 60 min with the anti-human gal-7 poly-
clonal antibody (R&D Systems, Minneapolis, MN) using
a 1:150 dilution. The slides were counterstained with
hematoxylin and bicarbonate. Each section was scanned at
a high resolution using the Nanozoomer Digital Pathology
System (Hamamatsu, Bridgewater, NJ). The study was
approved by the research ethics committee of the re-
search center at the Centre Hospitalier de l’Université
de Montréal (approval No. SL 05.019).Cell lines and reagents
The MCF-7 and MDA-MB-468 cell lines were provided
by Dr. Peter Siegel (Rosalind and Morris Goodman Cancer
Research Centre, McGill University, Montreal, QC,
Canada) and maintained in Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with 10% (v/v) FBS,
2 mM L-glutamine, 10 mM HEPES buffer and 1 mM
sodium pyruvate. SKBR3 cells, obtained from Dr. Sylvie
Mader (Institute for Research in Immunology and Cancer,
University of Montreal, Montreal, QC, Canada), were grown
in McCoy’s 5A Medium supplemented with 10% (v/v) FBS,
2 mM L-glutamine and 10 mM HEPES buffer at 37°C in a
humidified atmosphere containing 5% CO2. MCF10A and
MCF12A protein extracts were provided by Dr. Isabelle
Plante (INRS-Institut Armand-Frappier, Laval, QC, Canada).
All cell culture products were purchased from Life
Technologies (Burlington, ON, Canada). Cobalt chlor-
ide and lactose were purchased from Fisher Scientific
(Ottawa, ON, Canada). MG-132 was from Cayman Chem-
ical (Ann Arbor, MI). All other reagents were purchased
from Sigma-Aldrich (St. Louis, MO), unless otherwise
indicated.
Generation of stable transfectants expressing gal-7 and
gal-7 R74S
To obtain stable MCF-7 breast carcinoma transfectants
expressing gal-7, the cDNA encoding the human gal-7
(provided by Dr. Thierry Magnaldo) was cloned in srα
eukaryotic expression vector (kind gift of Dr. François
Denis) using SpeI and BamHI restriction enzymes. The
replacement of arginine 74 to serine (R74S) was intro-
duced by oligo-directed site-specific mutagenesis using
the forward (5′-GGC CGC GAG GAG TCC GGG CCG
GGC GTT CCT- 3′) and reverse (5′ –GGC CGC GAG
GAG TCC GGG CCG GGC GTT CCT- 3′) primers.
Controls were generated using MCF-7 breast carcinoma
cells transfected with the empty srα vector. Transfection
was carried out using Lipofectamine 2000 according to
the manufacturer’s instructions (Life Technologies). After
48 h of culture, transfected cells were allowed to grow in
complete medium containing 1 μg/ml of puromycin. Indi-
vidual colonies were expanded and gal-7 expression was
monitored by Western blot analysis. All experiments were
conducted with at least two independent clones express-
ing either wild type or mutant gal-7.
RNA isolation ant RT-PCR
Total cellular RNA was isolated from cells using the TRIzol
reagent (Life Technologies) according to the manufac-
turer’s instructions. First-strand cDNA was prepared from
2 μg of cellular RNA in a total reaction volume of 20 μL
using the reverse transcriptase Omniscript (QIAGEN,
Mississauga, ON, Canada). After reverse transcription,
human p53 (gene ID 7157, sense primer: 5′- CCA
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mer: 5′- TAT GGC GGG AGG TAG ACT GA -3′),
human p21 (gene ID 1026, sense primer: 5′- CTG
GAG ACT CTC AGG GTC GAA -3′ and antisense
primer: 5′- GGA TTA GGG CTT CCT CTT GGA -3′)
and GAPDH (gene ID 2597, sense primer: 5′- CGG
AGT CAA CGG ATT TGG TCG TAT-3′ and antisense
primer: 5′-CAG AAG TGG TGG TAC CTC TTC
CGA -3′) cDNAs were amplified using the following
conditions: 94°C for 3 min, followed by 25 to 35 cycles
of the following: 94°C for 40 seconds, 60°C for 40 seconds,
and 72°C for 40 seconds, followed by a final extension step
at 72°C for 10 min. PCR was performed in a thermal
cycler (Eppendorf, Mississauga, ON, Canada). The ampli-
fied products were analyzed by electrophoresis using 1.5%
agarose gels and SYBR Safe (Life Technologies) staining
and UV illumination.
Co-immunoprecipitation
MCF-7 stable transfectants expressing exogenous gal-7
and R74S mutant and MCF10A were transfected with
vectors encoding wild type p53 (Origene, Burlington,
MA). After 24 hrs, the cells were lysed in immunopre-
cipitation (IP) buffer containing 2% (v/v) CHAPS, 50 mM
Tris pH 7.5, 150 mM NaCl, 0.1 mM EDTA and protease
inhibitors (Roche, Laval, QC, Canada). Equal amounts of
whole cell protein extracts were used for each IP. Rabbit
anti-p53 antibody (FL393; Santa Cruz Biotechnology,
Santa Cruz, CA) or IgG control antibody (2 μg) were
incubated 10 min at room temperature with Dynabeads
Protein G (Life Technologies). The Dynabeads-antibody
complex was incubated with proteins overnight at 4°C.
After several washes in IP buffer, the protein complexes
were resuspended in Laemmli loading buffer. Immunopre-
cipitated proteins were separated on a 15% SDS-PAGE gel
and analyzed by Western blotting using anti-gal-7 and
anti-p53 as described below.
Western blot analysis
Whole cell extracts were suspended using RIPA lysis
buffer (Thermo Fisher Scientific, Rockford, IL) and prote-
ase inhibitors (Roche). Mitochondria and nuclear proteins
were extracted using a kit (Thermo Fisher Scientific;
Sigma-Aldrich) following the manufacturer’s instructions.
Protein concentrations were measured using a protein
assay reagent (Bio-Rad Laboratories, Mississauga, ON,
Canada). Equal amounts of proteins were separated on
SDS-PAGE and transferred onto nitrocellulose mem-
branes (Bio-Rad Laboratories). The membranes were first
blocked with 5% (v/v) milk in PBS/0.05% Tween 20 for 1
h and subsequently blotted overnight at 4°C with primary
antibodies: goat anti-human gal-7 polyclonal antibody
(1:1000; R&D Systems, Minneapolis, MN), rabbit anti-
p53 (FL393; 1:1000; Santa Cruz Biotechnology), rabbitanti-p21 (1:1000; Cell Signaling Technology, Danvers,
MA), rabbit anti-poly (ADP-ribose) polymerase (PARP)-1
(p25) monoclonal antibody (1:10000; Epitomics, Burlingame,
CA), rabbit anti-COX IV polyclonal antibody (1:1000; Cell
Signaling Technology), mouse anti-lamin A/C monoclonal
antibody (1:1000; Cell Signaling Technology), rabbit anti-β-
tubulin monoclonal antibody (1:10000; Cell Signaling
Technology), and mouse anti-β-actin monoclonal antibody
(1:20000; Sigma-Aldrich). Secondary antibodies consisted
of horseradish peroxidase conjugated donkey anti-goat
(R&D Systems), anti-rabbit or anti-mouse (GE Healthcare,
Buckinghamshire, England). Detection was performed by
the enhanced chemiluminescence method (GE Healthcare).
Immuno-electron microscopy
Cells were fixed in a 0.1% (v/v) gluteraldehyde and 4%
(v/v) paraformaldehyde solution and embedded in the
low viscosity embedding Spurr media. Ultrathin sections
were cut, placed on nickel grids and incubated in so-
dium metaperiodate. Samples were blocked in 1% (v/v)
BSA for 5 min, incubated 60 min in a goat anti-human
gal-7 polyclonal antibody (1:150) and 60 min in a rabbit
anti-goat 10 nm gold-conjugated secondary antibody
(1:20, Electron Microscopy Sciences, Hatfield, PA). Each
section were counterstained with uranyle acetate and
lead citrate and visualized using a Hitachi 7100 trans-
mission electron microscope.
Apoptosis detection by flow cytometry
The percentage of apoptotic cells was measured by two-
color flow cytometry using Alexa Fluor 488 annexin V
conjugate (Life Technologies) and propidium iodide (PI).
Briefly, 1.75 × 105 cells were treated with 150 μM cobalt
chloride overnight at 37°C without serum. Cells were
then harvested, stained and analyzed by flow cytometry
using a FacsCalibur (BD Biosciences, San Jose, CA).
Production of recombinant gal-7
Each of the DNA fragments coding for gal-7 and R74S
was cloned into pET-22b(+) using NdeI and HindIII re-
striction enzymes. Recombinant proteins were expressed
in E. coli BL21(DE3) at 37°C following addition of 1 mM
IPTG at an OD600 nm = 0.6-0.7 and an incubation of 4
h. Bacterial pellets were resuspended in lysis buffer
(0.7 mg/mL lysozyme, 10 mM Tris pH 8, 100 mM
NaCl, 1 mM EDTA, 1 mM DTT and protease inhibitor
cocktail), incubated for 1 h at 37°C and centrifuged for
30 min at 15 000 g (4°C). The supernatant was then
filtered and applied to a lactose-agarose column and
the protein was eluted in one mL fractions with 150
mM lactose. Fractions were analyzed by SDS-PAGE.
Gal-7 and R74S were dialyzed against 20 mM potassium
phosphate at pH 7.2 for all subsequent characterization
experiments. 15N-labeled samples were prepared by
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previously described [13].Solution NMR experiments
Proteins were at a concentration of 535 μM for gal-7
and 200 μM for gal-7 R74S. A 10% (v/v) D2O solution
was added to the protein samples for NMR spin-lock pur-
poses. Protein concentration was determined by UV–vis
spectrophotometry using an extinction coefficient of 8030
M−1 cm−1 at 280 nm [14]. 1H-15N HSQC spectra were
acquired at 800 MHz on a Varian (Agilent) NMR spec-
trometer equipped with a triple resonance probe and
pulsed-field gradients. All spectra were acquired at 310 K
as calibrated with a standard methanol sample. The 1H-15N
HSQC experiments were conducted with 256 t1 and 8192
t2 points with proton and nitrogen spectral widths of 3000
and 8000 Hz, respectively. Spectra were processed using
NMRPipe [15] and further analysed using Sparky [16].
The 1H-15N composite chemical shift differences (Δδ)
were calculated between wild-type and mutant enzymes




½. Only chemical shift variations
showing Δδ >0.02 ppm were considered significant.Isothermal titration calorimetry (ITC)
Lactose was reconstituted in a 20 mM potassium phos-
phate buffer at pH 7.2. Gal-7 and R74S were dialyzed in
the same buffer after purification. All experiments were
performed in a Nano ITC microcalorimeter (TA Instru-
ments, New Castle, DE) at 25°C with a stirring rate of
250 rpm. Pre-equilibrated solutions of 200 μM protein
and 6 mM ligand were used for each assay. A control ex-
periment was performed by titrating lactose into protein-
free buffer. Each experiment consisted of 20 injections of
2 μL ligand into protein, with an interval of 130 seconds
between injections. All experiments were performed at
least in triplicate. Data was analyzed and fitted using the
NanoAnalyze software v2.3.6 (TA Instruments).Figure 1 Expression of gal-7 in human mammary cancer tissues
and cell lines. (A) Typical expression patterns of gal-7 in normal
mammary tissues (myoepithelial cells) and in basal-like tumors collected
from patients. Detailed immunohistochemical analysis in different types
of breast cancer patients have been reported previously [6]. Scale bars,
300 μm (left) and 25 μm (right). (B) Cytosolic and nuclear fractions were
purified from basal-like breast cancer cells MDA-MB-468. Expression of
endogenous gal-7 was measured in both fractions by Western blotting.
β-tubulin and lamin A/C are shown as positive cytoplasmic and nuclear
expression controls, respectively. (C) Similar analysis showing expression
of gal-7 in purified mitochondrial fractions. β-tubulin and COX IV are
shown as positive cytoplasmic and mitochondrial expression controls,
respectively. (D) Gal-7 in human breast cancer cell lines. Expression was
measured by Western blot analysis from whole cell lysates. β-actin is
shown as a positive expression control.FITC conjugation and gal-7 binding assay
Briefly, 10 μl of a 2 mg/ml fluorescein isothiocyanate
(FITC)/DMSO solution was added to 300 μl of 1.7 μg/μl
recombinant wtgal-7 or R74S in a 0.1 M NaHCO3 pH
9.2 solution and incubated for 2 hrs at room temperature
on a roller. FITC-conjugated wtgal-7 or R74S was then
purified using a PD-10 sepharose column (GE healthcare)
and eluted with PBS containing 0.01% [v/v] sodium azide
(PBA). To measure FITC-wtgal-7 or R74S binding to cell
surface, 2.5 × 105 cells were incubated for 30 min with the
indicated concentrations. Cells were washed 2 times with
PBA and resuspended in 500 μl PBA. Samples were ana-
lyzed by FACSCalibur (BD Biosciences).Results
Subcellular localization of gal-7 in human breast cancer
cells
Analysis of gal-7 expression in normal mammary epithelium
shows positive gal-7 staining in both the nuclear and cyto-
plasmic compartments of myoepithelial cells (Figure 1A). A
similar pattern of expression was observed in tissue sections
obtained from patients with breast cancer, most notably in
sections from patients with basal-like breast cancer, where
gal-7 is preferentially expressed [6]. The expression of gal-7
in cytosolic and nuclear compartments was also confirmed
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MDA-MB-468 cells, which constitutively express gal-7
(Figure 1B-D). We also confirmed the ability of gal-7
to translocate to mitochondria in breast cancer cells, as
recently observed in human colon carcinoma cells [11].
Generation of the R74S mutant
Site-directed mutagenesis was used to generate mutants
of gal-7. A special attention was paid to arginine 74, the
structural equivalent of arginine 186 in human galectin-
3. Mutation R186S was previously shown to abolish the
biological function of galectin-3 [18]. The replacement
of arginine 74 to serine (R74S) was thus introduced in
the human gal-7 gene by oligo-directed site-specific mu-
tagenesis. To verify the integrity and structural perturba-
tions caused by the R74S mutation, we used solution
NMR spectroscopy, which provides a fast and highly
sensitive assessment of structural perturbations caused
by point mutations in proteins. For this purpose, the
wild-type gal-7 (wtgal-7) and variant R74S were isotopic-
ally labeled, overexpressed in E. coli BL21(DE3) and
purified to homogeneity. Their two-dimensional het-
eronuclear single quantum coherence spectra (1H-15N
HSQC) were then acquired and overlaid (Figure 2A).
Our 1H-15N HSQC spectral analysis showed that the
R74S mutation induced only limited and local changes
to the gal-7 fold (Figure 2A-D). Recombinant forms
of R74S and wtgal-7 were also equally effective at
forming dimers in solution (Figure 2E). Analysis ofFigure 2 Structural analysis of wild-type gal-7 and the R74S mutant.
(red) gal-7 at 310 K and 800 MHz. (B) 1H-15N chemical shift differences Δδ
of gal-7. The 1H-15N weighted average composite chemical shift difference




carbohydrate recognition domain (CRD) and the position of the carbohydr
E72 and R74. (D) Mapping of 1H-15N chemical shift variations (Δδ) between
Residues with chemical shift variations Δδ >0.05 ppm are plotted on the st
purple. (E) Immunoblots showing soluble monomeric and dimeric forms othe thermodynamic parameters of the proteins by isother-
mal titration calorimetry (ITC) indicated, however, that
binding of lactose to gal-7 was partially inhibited by the
R74S mutation, with a Κd value of 720 μM for the R74S
variant relative to 378 μM for the wild-type protein. A typ-
ical titration profile is shown in Additional file 1: Figure S1.
This finding was corroborated by our flow cytometric ana-
lysis showing that binding of recombinant R74S to glycan
receptors on the surface of Jurkat T cells was significantly
lower than that observed with the wild-type protein
(Additional file 2: Figure S2).
Functional characterization of the R74S mutant
Because MCF-7 cells have been extensively used as a
model system for human breast cancer, we have used
this cell line to express and further characterize the
R74S mutant. The relevance of MCF-7 model for our
studies was first established by expressing the wild-type
form of gal-7 (wtgal-7). Western blotting analysis of stable
transfectants showed that wtgal-7 was present in cyto-
solic, nuclear, and mitochondrial extracts of MCF-7
cells transfected with an expression vector encoding
wtgal-7 (Figure 3A-B), a pattern similar to that found
in MDA-MB-468 cells. Immunogold immunohistochem-
istry by electron microscopy (EM) confirmed the presence
of gal-7 in these subcellular compartments (Figure 3C-F).
The gold beads labeled mitochondria on the outer mem-
brane and inside the organelle. In all cases, gal-7 was
expressed in clusters, mostly being found inside the(A) Superimposed 1H-15N HSQC spectra of wild-type (green) and R74S
(ppm) caused by the R74S mutation mapped on the primary sequence
s (Δδ) were calculated between WT and variant R74S according to the
sional structure of gal-7 showing the general β-sheet topology of the
ate binding site, as delineated by residues H49, N51, R53, N62, W69,
wtgal-7 and variant R74S on the 3D structure of gal-7 [PDB: 3ZXF].
ructure of gal-7 (in blue). The position of the R74 residue is shown in
f recombinant gal-7 in a native gel.
Figure 3 Subcellular distribution of gal-7 in MCF-7 cells. (A) Cytosolic and nuclear fractions were purified from control (srα) cells and MCF-7
cells expressing gal-7. Expression of gal-7 was measured in both fractions by Western blotting. β-tubulin and lamin A/C are shown as positive
cytoplasmic and nuclear expression controls, respectively. (B) Similar analysis showing expression of gal-7 in purified mitochondrial fractions. β-tubulin
and COX IV are shown as positive cytoplasmic and mitochondrial expression controls, respectively. (C-F) Subcellular localization of gal-7 in MCF-7
as measured by electron microscopy. Scale bars, 500 nm (C) and 100 nm (D-F). (G) Effect of gal-7 on induction of apoptosis by doxorubicin.
Stable transfectants of MCF-7 cells expressing gal-7 were treated with 50 nM doxorubicin for 72 hrs at 37°C. Cells were then harvested and
PARP-1 cleavage levels were assayed by Western blotting.
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pressing wtgal-7 was also more resistant to apoptosis
induced by doxorubicin (dox) as compared to control
MCF-7 cells transfected with a (empty) control vector
(Figure 3G). These results corroborated our previous
data using the mouse 4T1 breast cancer cells [6]. We
thus examined whether the R→ S mutation at position
74 induced a change in the subcellular localization ofgal-7. Our Western blot analyses showed that this mu-
tation greatly reduced the expression of gal-7 in the
nucleus and mitochondria (Figure 4A-B). This effect
was confirmed by EM studies (Figure 4C-F). Interest-
ingly, however, we found that MCF-7 cells expressing
wild-type and R74S forms of gal-7 were equally resistant
to apoptosis induced by cobalt chloride, a hypoxia mim-
icking agent (Figure 5A-B), and by other anticancer drugs,
Figure 4 Subcellular distribution of the R74S mutant. The effect of the R74S mutation on the (A) nuclear and (B) mitochondrial localization
of gal-7, as measured by Western blot analysis of subcellular fractions. Membrane blots were incubated with anti-gal-7, anti-lamin A/C, anti-COX-
IV and anti-β-tubulin. Lamin A/C, COX-IV and β-tubulin were used as nuclear, mitochondrial and cytosolic markers, respectively. (C) Whole MCF-7
cell and distribution of galectin-7 R74S mutant in (D) cytoplasm, (E) nucleus and (F) mitochondria, as measured by electron microscopy. Scale
bars, 500 nm (C) and 100 nm (D-F).
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6A). In fact, MCF-7 cells expressing R74S were more re-
sistant to apoptosis induced by etoposide and dox.
Gal-7 reduces p53-induced p21 expression
Because MCF-7 cells express a wild-type form of p53
and that DNA damage response induced by dox is known
to increase the cyclin-independent kinase inhibitor p21
via a p53-dependent pathway, we took this opportunity to
examine the expression of p21 and p53 in MCF-7 cells ex-
pressing wtgal-7 and R74S. We found that both wtgal-7
and R74S inhibited dox-induced PARP-1 cleavage and p53
protein expression (Figure 6A-B). The inhibition of p53
correlated with a decrease in p21 protein expression and
CDKN1A mRNA (Figure 6B-C). Again, the inhibition by
R74S was stronger than that observed with the wild-type
form of gal-7. Furthermore, analysis of nuclear and cyto-
plasmic fractions showed that wild type and R74S mutant
gal-7 inhibited p53 nuclear translocation (Figure 7A).
Treatment of cells with MG-132, a well-known prote-
asome inhibitor, restored the p53 expression, suggesting
that both forms of gal-7 promote degradation of cytosolicp53 (Figure 7B). This possibility is supported by our
data showing that both forms of gal-7 co-precipitate
with p53 (Figure 7C-D). The ability of endogenous gal-
7 to co-precipitate with p53 was further confirmed
using MCF10A cells (Additional file 4: Figure S4).
Discussion
There is an increasing interest in the development of
galectin-specific inhibitors for the treatment of cancer.
Because galectins exert both intracellular and extracellu-
lar functions, a better understanding of their subcellular
localization in cancer cells is critical to promote the de-
velopment of new anti-cancer therapies directed at these
proteins.
Gal-7 is highly expressed at both the mRNA and protein
levels in tissues of patients with aggressive forms of can-
cer, including basal-like breast cancer subtype [6,19,20].
Experimentally, gal-7 has been shown to increase the
metastatic behavior of cancer cells while its suppression
reduces their metastatic behavior [6,21,22]. Like other
members of the galectin family, however, gal-7 has been
shown to have a dual role in cancer. While it promotes
Figure 6 Gal-7 and its R74S variant suppress PARP-1 cleavage,
p53 expression and p21 transcription induced by doxorubicin.
(A) Stable transfectants of MCF-7 cells expressing wild type or R74S
mutant gal-7 were treated with 50 nM doxorubicin for 72 hrs at 37°C
and immunoblotted with cleaved PARP-1-specific antibody. (B) Western
blot analysis showing p53, p21 and gal-7 protein expression following
doxorubicin treatment for 24 hrs. (C) mRNA levels of p53 and p21 were
assayed by semi-quantitative RT-PCR. β-actin and GAPDH were used as
loading controls.
Figure 5 Anti-apoptotic function of gal-7 is not altered by
R74S mutation. Effect of wild-type and mutated gal-7 on (A)
PARP-1 cleavage and (B) Annexin V positive cells induced upon
treatment with 150 μM CoCl2. (C) Western blot analysis of PARP-1
cleavage for increasing doses of etoposide for 24 hrs at 37°C. Controls
included stable MCF-7 cells transfected with the empty (srα)
expression vector.
Grosset et al. BMC Cancer 2014, 14:801 Page 8 of 10
http://www.biomedcentral.com/1471-2407/14/801cancer progression in many types of cancer, it may exert
an anti-tumor activity in other types of cancer, such as
urothelial carcinoma and colon cancer. In all cases, the
role of gal-7 in apoptosis was associated with its intracel-
lular localization, as shown by the strong cytosolic and nu-
clear immunoreactivity with anti-gal-7 antibodies [6,23].
Our model system with the R74S mutant will thus be use-
ful to determine whether translocation to mitochondria
and nucleus modulates the ability of gal-7 to modulate
apoptosis in other cancer cell types.
Because R74 is located in the vicinity of the CRD, it is
not surprising that a mutation at this position reduces
the affinity to lactose or the binding to cell surface gly-
coproteins. It may also affect the fine specificities of ligand
recognition in the ligand binding groove, as suggested by
the tridimensional structure of gal-7 [4]. We expect, how-
ever, that the R74S mutation will not affect the protein-
protein interactions that gal-7 displays with proteins such
as Bcl-2 and Smad3 [9,11]. Similarly to galectin-3 that uti-
lizes synexin for its translocation to the perinuclear mito-
chondrial membranes, gal-7 might also require the aid ofsimilar transport proteins for its translocation [24]. As
such, the cytosolic presence of the R74S mutant is poten-
tially due to the loss of the interaction between gal-7 and
its transport proteins resulting in its pronounced cytosolic
localization. Alternatively, the mutation at the R74 pro-
moting the cytosolic sequestration of gal-7 may allow en-
hanced binding to cytosolic proteins increasing as such
various cytoplasmic signaling pathways. Nevertheless, fu-
ture studies will be needed to determine the specific
mechanism by which gal-7 translocates to mitochondria
and to the nucleus.
Our results suggest that gal-7 may be involved in the
regulation of p21 expression. These results may thus pro-
vide a new mechanism underlying the functions of gal-7 in
apoptosis and warrant further investigation. Specifically, we
found that the R74S mutation does not alter the prolifera-
tion rate of breast cancer cells (Additional file 5: Figure S5).
Figure 7 Decreased of p53 nuclear translocation through
proteasomal degradation induced by cytoplasmic gal-7. (A)
Cytosolic and nuclear fractions were purified from control (srα) cells
and MCF-7 cells expressing wild type or mutated gal-7 after doxorubicin
treatment. Expression of p53, p21 and gal-7 was measured in both
fractions by Western blotting. β-tubulin and lamin A/C are shown
as positive cytoplasmic and nuclear expression controls, respectively.
(B) Cells were treated with 10 μM MG-132 for 0, 2, and 6 hrs. Total
cellular extracts were subjected to Western blot analysis for p53,
gal-7 and β-actin. Immunoprecipitation (IP) experiments showing
p53 interaction with (C) wild type and (D) R74S mutant of gal-7 in
MCF-7 cells. Whole-cell lysates were made from MCF-7 cells transfected
with a construct expressing p53. Lysates were immunoprecipitated
with anti-p53 or a control IgG antibody, and immunoblot analysis was
performed with anti-gal-7.
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and the co-immunoprecipitation of gal-7 with p53 suggests
that gal-7 may help to stabilize cytosolic p53, possibly by
modulating its interaction with MDM2. Whether gal-7 dir-
ectly binds to p53 or belongs to the p53 multimolecular
complex is currently unknown. Although glycosylation
of p53 has been reported [25-27] and that some p53-
interacting proteins are glycosylated [28], our observa-
tion that R74S also co-immunoprecipitates with p53
suggests that such interaction could be CRD-independent.
Such CRD-independent function for galectins is not un-
common, especially for intracellular galectins [3]. Another
possibility that may explain lower levels of nuclear p53
protein and reduced p21 activation is that gal-7 may be
part of a complex network of interrelated mechanismsthat regulate the nucleo-cytoplasmic transport of p53 fol-
lowing cellular stress. These possibilities are currently
under investigation.Conclusions
In the present work, we have shown that: 1) a mutation
at position 74 inhibited translocation of gal-7 to the
mitochondria and the nucleus, sequestering gal-7 to the
cytosolic compartment; 2) such decrease of gal-7 expres-
sion in the nucleus and mitochondria does not impair
the ability of gal-7 to drug-induced apoptosis; in fact,
the R74S mutant protected even more cells from apop-
tosis induced by anti-cancer drugs, and 3) sequestration
of gal-7 to the cytosol impaired the translocation of p53
to the nucleus and the upregulation of p21. Taken to-
gether, these results suggest that targeting cytosolic gal-7
in breast cancer cells may be a valuable strategy for the
treatment of this disease.Additional files
Additional file 1: Figure S1. Isothermal calorimetric titration of gal-7
with lactose. (Top) Typical ITC experiment carried out by adding 2 μl aliquots
of 6 mM lactose to 200 μM wtgal-7 or R74S. (Bottom) Heat released per mole
of lactose injected as a function of the sugar / protein molar ratio. The titration
was obtained at 25°C in 20 mM potassium phosphate buffer, pH 7.2.
Additional file 2: Figure S2. Binding of recombinant wtgal-7 and R74S
to Jurkat T cells. Increasing concentrations of recombinant FITC-labeled
wtgal-7 or R74S were added to Jurkat T cells. Binding was measured by
flow cytometry after 30 min of incubation at 4°C.
Additional file 3: Figure S3. Clusters of gal-7 in MCF-7 cells observed
by electron microscopy. Transmission electron micrographs showing
gal-7 clusters (arrows) in (A) the cytoplasm, (B) nucleus, and (C) mitochondria
of MCF-7 stable transfectants expressing gal-7. In (D), quantitative
assessment of the number of immunogold particles per clusters as
measured from transmission electron micrographs.
Additional file 4: Figure S4. Interaction of endogenous gal-7 with p53
in MCF10A cells. Immunoprecipitation (IP) experiments showing p53
interaction with endogenous gal-7 in MCF10A cells. Whole-cell lysates
were made from MCF10A cells transfected with a construct expressing
p53. Lysates were IP with anti-p53 or a control IgG antibody, and immunoblot
analysis was performed with anti-gal-7.
Additional file 5: Figure S5. Cellular proliferation of MCF-7 is not
significantly affected by gal-7 and R74S variant. Stable transfectants
of MCF-7 cells expressing empty vector (ctrl), wild type or R74S mutant
gal-7 were seeded at 5000 cells per well in E-Plates 96 and observed for a
period of 72 h. Dynamic proliferation assay was achieved via xCELLigence
real-time cell analyzer.Abbreviations
gal-7: Galectin-7; wtgal-7: Wild-type galectin-7; CRD: Carbohydrate
recognition domain; dox: Doxorubicin.
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